Getting Mounjaro from a GP: how the process actually works in the UK

Step 1: finding out whether your GP practice is prescribing Mounjaro at all

From 1 April 2026, GP practices in England gained the ability to prescribe tirzepatide under the updated GP contract. This is not automatic, participation is optional, and uptake varies considerably by practice and integrated care board. The first practical step is a straightforward one you can do in about thirty seconds: call your surgery or check its website to ask whether it is currently prescribing weight-management medicines under the new arrangements.

Even where a practice has signed up, it must follow NICE's appraisal of tirzepatide (TA1026) for NHS prescribing. The current NHS threshold is a BMI of 40 or above, alongside four or more qualifying conditions from a defined list: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. The BMI threshold is 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. A second cohort covering BMI 35–39.9 with four or more conditions was activated in June 2026, with further expansions planned for 2027.

If your practice is not yet participating, or you do not meet the current NHS criteria, your GP may still discuss your options. Some practices refer patients to specialist weight management services where a GP-led weight management pathway may be available under different arrangements. Worth checking with them directly.

Step 2: the clinical assessment itself

Assuming your practice is participating and you broadly meet the criteria, your GP will carry out a clinical assessment before any prescription is issued. This is not a formality. Tirzepatide is a Black Triangle medicine under additional MHRA monitoring, and the NHS's guidance on tirzepatide makes clear that prescribers must confirm suitability against your full medical history, not just your BMI.

Expect your GP to review current medications (some interact with tirzepatide), check for conditions that would make treatment unsuitable, discuss your weight history, and explain the lifestyle changes (reduced-calorie diet and increased physical activity) that must accompany treatment. These are not optional add-ons; they are part of the licensed indication. Under NHS arrangements, the practice must also ensure you have access to "wraparound" diet and activity support.

The assessment may happen in a single appointment or across two, depending on how much baseline information your GP already has. If you are on oral contraceptives, your GP should note that for the first four weeks of treatment and after each dose increase, an additional contraceptive method is advisable because tirzepatide can slow gastric emptying and reduce pill absorption. The fuller picture on clinical criteria for Mounjaro from a GP covers this in more detail.

Step 3: what happens if you do not qualify on the NHS route

This is where most people find themselves right now. The NHS thresholds are deliberately narrow in this first phase, and even patients who do qualify may face waits while practices build their prescribing capacity. For many, the practical alternative is a private prescription from a GPhC-registered online pharmacy.

The licensed private eligibility criteria are broader than the current NHS thresholds: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as prediabetes, high blood pressure, or high cholesterol. A prescriber still assesses every application individually, BMI alone is never the whole picture. If you are curious about where Mounjaro is manufactured and comes from, that background is covered separately, alongside details on what private treatment typically costs at the cost of Mounjaro in the UK.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, not by automated decision-making. If you are clinically suitable, treatment can be dispatched the same day you are approved. You can verify our pharmacy on the GPhC register (premises registration 9012878) at pharmacyregulation.org.

A note on side effects and ongoing review, whichever route you take

Whether Mounjaro comes via your GP or a private prescriber, the medicine and its profile are the same. The most commonly reported effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and reduced appetite. These tend to be most noticeable in the early weeks and usually ease as your body adjusts to each dose level. Severe or persistent stomach pain that travels to your back warrants prompt medical attention, as the MHRA highlighted in a January 2026 Drug Safety Update on GLP-1 medicines and pancreatitis.

Skin reactions at the injection site are less common; if you develop a rash, a guide to Mounjaro-related skin reactions explains what to watch for and when to contact your prescriber. Any suspected side effects can be reported directly to the MHRA via the Yellow Card scheme.

Ongoing clinical review matters just as much as the initial assessment. Dose increases should be evidence-led; the prescriber (GP or otherwise) is checking both that treatment is working and that it remains appropriate for you. If you have questions about the medicine itself, our tirzepatide overview covers the mechanism, the trial evidence, and the licensing background in plain language.

If you have looked at the NHS route and found you do not currently qualify, or simply want to get started without a waiting list, you are welcome to start your free consultation with our prescribing team.